Evidence map›Paper›PMID 30642281›Full record

ArticleBMC cancer2019

CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer.

Andrea Rebeca Bustos-Carpinteyro, Carla Oliveira, Abel Sousa, Patricia Oliveira, Hugo Pinheiro, Joana Carvalho, María Teresa Magaña-Torres, María Guadalupe Flores-Miramontes, Adriana Aguilar-Lemarroy, Luis Felipe Jave-Suárez and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Genes · 2022
    Article
  5. Review
  6. Characteristics of cancer susceptibility genes mutations in 282 patients with gastric adenocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Andrea Rebeca Bustos-CarpinteyroDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada N. 800, Col. Independencia, C. P. 44340, Guadalajara, Jalisco, México.
Carla OliveiraExpression Regulation in Cancer, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Abel SousaExpression Regulation in Cancer, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Patricia OliveiraExpression Regulation in Cancer, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Hugo PinheiroExpression Regulation in Cancer, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Joana CarvalhoExpression Regulation in Cancer, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
María Teresa Magaña-TorresDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada N. 800, Col. Independencia, C. P. 44340, Guadalajara, Jalisco, México.
María Guadalupe Flores-MiramontesDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Adriana Aguilar-LemarroyDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Luis Felipe Jave-SuárezDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Jorge Peregrina-SandovalLaboratorio de Inmunobiología, Departamento de Biología Celular y Molecular. Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, CP 45510, Nextipac, Jalisco, México.
José Alfonso Cruz-RamosInstituto Jalisciense de Cancerología, CP 45180, Guadalajara, Jalisco, México.
Josefina Yoaly Sánchez-LópezDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada N. 800, Col. Independencia, C. P. 44340, Guadalajara, Jalisco, México. yosalo1795@yahoo.com.
Mexican Social Security Institute · MXUniversidade do Porto · PTi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInstituto Jalisciense de Cancerología · MXUniversidad de Guadalajara · MX

Funding

Consejo Nacional de Ciencia y Tecnología Ciencia Básica 2013-1-222972Fondo de Investigación en Salud (FIS), Instituto Mexicano del Seguro Social. FIS/IMSS/PROT/G13/1189
6 · The paper itself

Abstract

backgroundDiffuse gastric cancer (DGC) is associated with the reduction or absence of the expression of the cell adhesion protein E-cadherin (encoded by the CDH1 gene). Molecular characteristics are less well described for mixed gastric cancer (MGC). The main somatic alterations that have been described in the CDH1 gene are mutations, loss of heterozygosity (LOH) and promoter methylation. The aim was to analyze CDH1 somatic alterations in Mexican patients with diffuse and mixed gastric cancer.

methodsWe searched for mutations in the CDH1 gene in tumor DNA from DGC (n = 13) and MGC (n = 7) patients by next generation sequencing (NGS). Validation of findings was performed using Sanger sequencing. LOH was analyzed using dinucleotide repeat markers surrounding the CDH1 gene, and methylation was investigated by DNA bisulfite conversion and sequencing. E-cadherin protein deficiency was analyzed by immunohistochemistry.

resultsSeventeen point variants were identified by NGS, 13 of them were validated by Sanger sequencing. Only 1/13 had not been previously reported (c.-137C > A), and 12/13 were already reported as polymorphisms. Two DGC cases presented LOH at the locus 16q22.1 (13.3%). CDH1 promoter methylation was positive in (7/11) 63.6% and (4/6) 66.6% of the cases with DGC and MGC, respectively. E-cadherin protein deficiency was observed in 58.3% of DGC cases while 100% in MGC cases.

conclusionsWhile no pathogenic somatic mutations were found that could explain the diffuse histology of gastric cancer in DGC and MGC, methylation was the most common somatic inactivation event of the CDH1 gene, and LOH was rare. The previously unreported c.-137C > A variant modify the CDH1 gene expression since it alters the binding sites for transcription factors.

Indexed as

MutationAllelesAntigens, CDCadherinsDNA MethylationDNA Mutational AnalysisFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansLoss of HeterozygosityMaleMexicoPolymorphism, GeneticPromoter Regions, GeneticAntigens, CDCadherinsCDH1 protein, humanCDH1 mutationsDNA sequencingGastric CancerLOHMethylation

Identifiers

PMID30642281
PMCPMC6332846
OpenAlexW2947876953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.